HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

HLA-B18 as a risk factor of short-term progression to severe liver fibrosis in HIV/HCV co-infected patients with absent or minimal fibrosis: implications for timing of therapy.

Abstract
Our aim was to analyze the influence of HLA-B haplotypes on liver fibrosis progression in HIV/hepatitis C virus (HCV) co-infected patients. Retrospective longitudinal study including HIV/HCV, non-cirrhotic and HCV treatment-naïve patients. The main outcome variable was liver fibrosis progression of at least one stage. One hundred and four patients constituted the study population (F0-F1: 62 (59.6%); F2: 22 (21.2%); F3: 20 (19.2%)). During a median follow-up of 54.5 months (IQR: 26.2-77), 45 patients (43.3%) showed an increase in the stage of liver fibrosis (time to event: 29 (IQR: 14-49.5) months). HLA-B18pos patients more frequently had a higher and faster fibrosis progression rate (73.3%; 24 (IQR: 8-29) months) than HLA-B18neg patients (38.2%; 34.5 (IQR: 14.7-51.2) months). This association was also observed in the development of F3-F4 fibrosis among F0-F2 patients (HLA-B18pos: 69.2%; 18 (6.5-37) months vs HLA-B18neg: 28.2%; 37 (IQR: 19-52) months). These results could impact the timing of HCV therapy in F0-F2 patients.
AuthorsM Frías, D Rodríguez-Cano, F Cuenca-López, J Macías, A Gordon, B Manzanares-Martín, J A Pineda, Á Camacho, J Torre-Cisneros, J Peña, A Rivero-Juárez, A Rivero
JournalThe pharmacogenomics journal (Pharmacogenomics J) Vol. 17 Issue 6 Pg. 551-555 (12 2017) ISSN: 1473-1150 [Electronic] United States
PMID27241060 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • HLA-B18 Antigen
Topics
  • Adult
  • Coinfection
  • Disease Progression
  • Female
  • Genotype
  • HIV Infections (complications, drug therapy, genetics, virology)
  • HLA-B18 Antigen (genetics)
  • Hepatitis C (complications, drug therapy, genetics, virology)
  • Humans
  • Liver Cirrhosis (etiology, genetics, immunology)
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Factors
  • Severity of Illness Index
  • Survival Analysis
  • Time Factors
  • Treatment Failure
  • Viral Load

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: